TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Moderate aortic stenosis linked to heightened risk of death—should TAVR, surgery be considered?
Researchers tracked data from more than 400,000 patients for a new meta-analysis, presenting their findings in the Journal of the American Heart Association.
New-look TAVR valve shows early promise in patients with severe AS
One-year data presented at SCAI's annual meeting suggest interventional cardiologists could soon have a new way to treat severe aortic stenosis.
TAVR linked to lower stroke risk than SAVR in patients with AS and cardiogenic shock
TAVR is also associated with a lower risk of acute kidney injury in this patient population. In-hospital mortality rates, however, are similar between the two treatment options.
SCAI 2024 Scientific Sessions to focus on TAVR, PAD and other key trends in interventional cardiology
Interventional cardiologists from all over the world will gather for three days of educational sessions, late-breaking presentations, live cases and more. The festivities begin Thursday, May 2, in Long Beach, California.
Next-day discharge after TAVR with a self-expanding valve: 4 key takeaways
Researchers explored STS/ACR data from nearly 30,000 TAVR patients, presenting their findings in the Journal of the American Heart Association.

Video of Michael Reardon, MD, explaining details from the Evolute Low Risk 4-year results at TCT 2023.

TAVR triumphs over surgery: Exploring 4-year data from the Evolut Low Risk trial

Michael Reardon, MD, discussed his team's late-breaking results at TCT 2023 in San Francisco.

October 30, 2023

PARTNER 3, Evolut and more: TAVR takes the spotlight in 4 late-breaking clinical trials at TCT 2023

All eyes were on TAVR during the first round of late-breaking clinical trials at TCT 2023 in San Francisco. Researchers shared key updates related to devices from Edwards Lifesciences, Medtronic, Boston Scientific and JenaValve Technology.

October 25, 2023

Akhil Narang, MD, director of the echocardiography laboratory at Northwestern Medicine explains the latest trends in structural heart interventional imaging. #ASE #ASE23 #ASE2023 #structuralheart #echofirst

The evolving roles of TEE and ICE in structural heart interventions

Akhil Narang, MD, explained that the two technologies can be used together to deliver high-quality patient care.

October 23, 2023

A late-breaking science presentation at the annual TCT interventional cardiology meeting.

Late-breaking clinical trials at TCT 2023

Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.

October 17, 2023

The central figure from the study "Predictors and Variation in Cardiac Rehabilitation Participation After Transcatheter Aortic Valve Replacement study 2023," showing the wide variation in the percentage of patients who receive post-TAVR rehab among TAVR patients in Michigan.

Less than one-third of TAVR patients enter cardiac rehab

Only about 30% of patients who underwent TAVR in Michigan participated in cardiac rehabilitation within 90 days after discharge.

October 16, 2023

Medtronic's Evolut FX TAVR valve, designed with 3 golden markers that improve alignment.

Medtronic receives CE mark approval for Evolut FX TAVR system

The self-expanding valve, already approved by the FDA, was designed with three gold markers to boost implanter efficiency, an updated catheter tip and a more flexible delivery system.

October 13, 2023

The SavvyWire TAVR guidewire by OpSens / Haemonetics

Haemonetics to acquire medical device company known for its TAVR guidewires for $253M

Haemonetics expects the deal to increase its short- and long-term revenue. The all-cash transaction should close by January 2024.

October 11, 2023

The Pioneer TAVR system from KOKA Lifesciences

New TAVR system for pure aortic regurgitation used for first time, linked to ‘excellent’ short-term outcomes

Researchers explored data from the first 10 patients treated with a new self-expanding TAVR device from KOKA Lifesciences. After 30 days, there were no patient deaths and only one adverse event.

October 10, 2023

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

TAVR

Moderate aortic stenosis linked to heightened risk of death—should TAVR, surgery be considered?

New-look TAVR valve shows early promise in patients with severe AS

TAVR linked to lower stroke risk than SAVR in patients with AS and cardiogenic shock

SCAI 2024 Scientific Sessions to focus on TAVR, PAD and other key trends in interventional cardiology

Next-day discharge after TAVR with a self-expanding valve: 4 key takeaways

Around the web